Insurance companies routinely state that they refuse to pay for costs linked with patients’ rare cancers because recommended treatments are experimental and unproven.
Imagine the following as a business plan model for an insurer.
“We live in a time when even outlandish arguments can sometimes win the day.”
First of all, let’s clarify those acronyms. We are referring to UM and UIM, which are commonly used shorthand designations relevant to automobile insurance coverage. They come into play when a driver involved in an accident lacks sufficient coverage to fully compensate another motorist.
William E. Bennett Jr. has some strong views concerning insurers’ role in the treatment-approval process for patients, and he is not shy about communicating them.
No reasonable person begrudges an insurance company’s efforts to maximize corporate profits, provided it does not compromise an insured’s health in the process.
Oklahoma residents doing their homework prior to making a major consumer decision duly focus on comparative shopping.
Short answer to today’s above-posed blog headline query: maybe.
Aggrieved consumers in Oklahoma and nationally are hardly without resources when they turn for information concerning purposeful actions to take in the wake of insurance company denials. A simple online search query yields scores of websites addressing that issue in some fashion.
The concept is simple enough and eminently logical from an insurer’s perspective. It’s called “step therapy,” and it works as follows, illustrated through a representative scenario.